Eventide Asset Management LLC Sells 68,993 Shares of Abivax SA Sponsored ADR $ABVX

Eventide Asset Management LLC lessened its position in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 17.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 327,911 shares of the company’s stock after selling 68,993 shares during the period. Eventide Asset Management LLC’s holdings in Abivax were worth $44,221,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of ABVX. EverSource Wealth Advisors LLC increased its stake in Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after purchasing an additional 369 shares in the last quarter. Bank of America Corp DE increased its stake in Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after purchasing an additional 1,990 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in Abivax by 661.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock valued at $53,000 after purchasing an additional 344 shares in the last quarter. WPG Advisers LLC increased its stake in Abivax by 125.9% in the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after purchasing an additional 253 shares in the last quarter. Finally, Cubist Systematic Strategies LLC increased its stake in Abivax by 34.3% in the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock valued at $63,000 after purchasing an additional 2,595 shares in the last quarter. Institutional investors own 47.91% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Wolfe Research set a $136.00 price target on shares of Abivax in a report on Wednesday, June 3rd. Truist Financial cut their price objective on shares of Abivax from $140.00 to $135.00 and set a “buy” rating on the stock in a research report on Tuesday, June 2nd. Oddo Bhf reaffirmed an “outperform” rating on shares of Abivax in a research report on Thursday, April 9th. Citigroup reaffirmed an “outperform” rating on shares of Abivax in a research report on Tuesday, June 2nd. Finally, BTIG Research reaffirmed a “buy” rating and issued a $150.00 price objective on shares of Abivax in a research report on Tuesday, June 2nd. Twelve research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Abivax has a consensus rating of “Moderate Buy” and an average target price of $130.08.

Abivax Stock Down 4.3%

Shares of Abivax stock opened at $96.55 on Friday. The stock has a market cap of $7.69 billion, a P/E ratio of -18.53 and a beta of 0.69. The business’s 50 day moving average is $116.01 and its 200-day moving average is $119.12. Abivax SA Sponsored ADR has a 12-month low of $5.69 and a 12-month high of $148.83.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The firm had revenue of $1.56 million during the quarter, compared to analyst estimates of $0.40 million. On average, sell-side analysts expect that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.